Will Moderna’s norovirus vaccine meet its Phase 3 primary efficacy endpoint?

Question

This market will resolve YES if Moderna’s final primary efficacy analysis of the ongoing Phase 3 mRNA-1403 norovirus vaccine trial meets the protocol-defined statistical success criterion for its primary efficacy endpoint. The earlier interim analysis is expressly excluded: failure to stop early is not treated as the final result.

Antibody responses, a favourable subgroup, safety alone or a secondary endpoint do not qualify if the primary efficacy endpoint fails. Use the population, case defini

Problyx · Accepted Answer

No — the community forecast puts this at 57%.

Problyx · Answer

Yes — the community forecast puts this at 43%.